Phase 3 N=630 Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)
HIV Infections
Primary: Treatment Response at Week 48 — 33.80; 16.20 percentage of participants — p=0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=165 Study in Women With Idiopathic Menorrhagia to Determine the Reduction in Menstrual Blood Loss (MBL) After Treatment With the Levonorgestrel-releasing Intrauterine System (IUS)
Menorrhagia
Primary: The Change in Absolute Value From Baseline Menstrual Blood Loss (MBL) to the End-of-study MBL (Cycle 6) — -128.78; -17.7 milliliter (mL) — p=<0.001
Phase 3 N=394 Assessment of the Transfer of Using Levonorgestrel Intrauterine System (LNG IUS) as a Contraceptive to Using it as Part of Hormone Replacement Therapy (HRT).
Menopause
Primary: Number of Bleeding Days — 0; 0; 0; 0 Bleeding days — p=0.128
Phase 3 N=4,065 An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020)
Condylomata Acuminata
Primary: Base Study: Incidence of Human Papillomavirus (HPV) Type 6/11/16/18-related External Genital Warts, Penile/Perianal/Perineal Intraepithelial Neoplasia (PIN), Penile…
Phase 3 N=333 Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05583)
Allergic Rhinitis
Primary: Change From Baseline in Average AM/PM PRIOR Nasal Congestion Score Over 15 Days — -0.71; -0.40 Units on a scale — p=<0.001
Phase 3 N=236 Duloxetine Versus Placebo in Chronic Low Back Pain
Back Pain Without Radiation
Primary: Change From Baseline to Week 13 in Brief Pain Inventory (BPI), 24-hour Average Pain Scores — -2.32; -1.50 units on a scale — p=0.004
Phase 3 N=138 Safety and Efficacy Study of Axid Use in Infants Suffering From Gastroesophageal Reflux Disease (GERD)
Gastroesophageal Reflux Disease · GERD · Heartburn
Primary: Infant Gastroesophageal Reflux Questionnaire Revised (I-GERQ-R) Success — 27; 32; 31 participants — p=0.528
Phase 3 N=43 Extension Study of Patients Successfully Treated by Ziprasidone in Study A1281031
Schizophrenia
Primary: Number of Participants With Categorical Scores on Clinical Global Impression - Improvement (CGI-I) — 13; 30; 10; 20 participants
Phase 3 N=256 A Multicenter, Randomized, Open Label Study to Evaluate the Lipid Lowering Efficacy and Safety of Vytorin® 10/20 vs. Atorvastatin 10mg in Hypercholesterolemia Patients With Metabolic Syndrome in Korea (0653A-129)(COMPLETED)
Hypercholesterolemia
Primary: Mean Percent Change of Low Density Lipoprotein-Cholesterol (LDL-C) From Baseline After 8 Weeks. — -49.29; -38.05 Percent of Baseline Value — p=<0.0001
Phase 3 N=539 Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab
Crohn's Disease
Primary: Response Status With Response Defined as at Least 100 Point Decrease in Crohn's Disease Activity Score (CDAI Score) From Baseline in the Induction Phase — 334; 205…
Phase 3 N=40 Light Emitting Diode (LED) for the Treatment of Wrinkles
Skin Aging · Photoaging of Skin
Primary: Percent Change From Baseline in Microtopographic Profilometry Ra Values (Skin Roughness). — 3.62; 18.57 Percent change post-treatment — p=<0.0001
Phase 3 N=47 Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Familial Cold Autoinflammatory Syndrome (FCAS) · Familial Cold Urticaria · Muckle-Wells Syndrome (MWS)
Primary: Change From Baseline to Week-6 (Part A) Endpoint in Mean Key Symptom Score (KSS) — 2.4; 3.1; 2.1; 0.5 Units of a Scale — p=<.0001
Phase 3 N=4,447 RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes
Diabetes Mellitus, Type 2
Primary: Number of Participants With Cardiovascular Death/Cardiovascular Hospitalisation Events — 321; 323 participants
Phase 3 N=351 Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05529)
Allergic Rhinitis
Primary: The Change From Baseline in Average AM/PM PRIOR Nasal Congestion Score Over 15 Days — -0.64; -0.49 Units on a scale — p=0.006
Phase 3 N=130 Follow up Trial for Keppra (Levetiracetam) as Monotherapy in Patients With Newly Diagnosed Epilepsy Coming From N01175 (NCT00175903).
Epilepsy
Primary: Assessment of Safety of Levetiracetam as Per Adverse Event (AE) Reporting in Open-label Therapy Phase — 40; 8; 1; 16 participants